Lymphocyte Depleted Hodgkin Lymphoma, Extranodal and Solid Organ Sites (C81.39)

Name of the Condition

• Common Name: Lymphocyte Depleted Hodgkin Lymphoma, Extranodal and Solid Organ Sites
• Medical Terms: LD Hodgkin Lymphoma, Lymphocyte-Depleted Hodgkin Disease (extranodal and solid organ sites)

Summary

Lymphocyte depleted Hodgkin lymphoma (LD Hodgkin lymphoma) is a rare and aggressive subtype of Hodgkin lymphoma. It is characterized by a scarcity of lymphocytes and a predominance of Reed-Sternberg cells in affected lymph nodes or tissues. This subtype often presents at an advanced stage and may involve extranodal sites, such as the liver or bone marrow. LD Hodgkin lymphoma is associated with a poorer prognosis compared to other Hodgkin lymphoma subtypes, though treatment advances have improved outcomes.

Causes

The exact cause of lymphocyte depleted Hodgkin lymphoma is not fully understood. It is thought to result from a combination of genetic mutations and environmental factors. Unlike other Hodgkin lymphoma subtypes, Epstein-Barr virus (EBV) is frequently associated with LD Hodgkin lymphoma, suggesting a potential viral role in its development. Genetic abnormalities and immune system dysregulation may also contribute.

Risk Factors

• Age: Most commonly diagnosed in adults, particularly those over 50.
• Immune Status: Weakened immunity (e.g., from HIV/AIDS or immunosuppressive therapy) increases risk.
• Epstein-Barr Virus: Prior infection is strongly associated with this subtype.
• Geographic Region: Higher incidence in certain regions, possibly due to environmental or genetic factors.

Symptoms

Symptoms may include painless swelling of lymph nodes, fever, night sweats, unexplained weight loss, fatigue, and itching. When extranodal or solid organ sites are involved, symptoms may relate to the affected area, such as abdominal pain or organ dysfunction.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging (e.g., CT, PET scans), and biopsy of affected tissue. Histopathological examination confirms the presence of Reed-Sternberg cells and the lymphocyte-depleted pattern. Staging determines the extent of disease, including involvement of extranodal sites.

Treatment Options

Treatment typically includes chemotherapy, often combined with radiation therapy for localized disease. Stem cell transplantation may be considered for advanced or refractory cases. Targeted therapies and immunotherapies are under investigation for improved outcomes.

Prognosis and Follow-Up

Prognosis is generally poorer than other Hodgkin lymphoma subtypes due to advanced presentation and aggressive behavior. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or complications.

Complications

Complications may include treatment-related toxicities, infection due to immunosuppression, organ damage from disease progression, and secondary malignancies. Advanced disease can lead to organ failure or severe systemic symptoms.

Lifestyle & Prevention

No specific preventive measures exist, but maintaining a healthy immune system and avoiding known risk factors (e.g., immunosuppressive conditions) may reduce risk. Supportive care, including nutrition and stress management, can improve quality of life during treatment.

When to Seek Professional Help

Seek medical attention for persistent lymph node swelling, unexplained weight loss, fever, or other systemic symptoms. Prompt evaluation is critical for early diagnosis and treatment.

Tips for Medical Coders

Code C81.39 is used for lymphocyte depleted Hodgkin lymphoma involving extranodal and solid organ sites. Documentation should specify the site(s) of involvement (e.g., liver, spleen, or other organs) to support accurate coding. Ensure the diagnosis aligns with histopathological confirmation of the lymphocyte-depleted subtype and extranodal/solid organ involvement.